Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

ABBV-2222 + ABBV-3067 + ABBV-191

Phase Two

Phase Two

Therapeutic Approach

Restore CFTR Function

This program is studying a combination therapy combining two CFTR correctors and a potentiator. Correctors are a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, potentiators help facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell.


A phase 2 study to test the safety and effectiveness of ABBV-3067 both alone and in combination with ABBV-2222 is currently underway.


This program is sponsored by Abbvie and is being conducted within the Therapeutics Development Network.

Contact us about ABBV-2222 + ABBV-3067 + ABBV-191 >